OptaBlate (Bone Tumor Ablation System)

2022: System Announcement

On September 20, 2022, Stryker announced the launch of the OptaBlate bone tumor ablation system. This solution will help doctors easily adapt their procedures, the system helps to reduce ablation time by three minutes, the manufacturer claims.

The OptaBlate system features four probes and Stryker's patented micro-infusion technology. Adding this system to the portfolio of interventional spinal therapies extends its competence in vertebral augmentation and radiofrequency ablation, the developers said. OptaBlate also complements the portfolio of treatment options for metastatic vertebral body fractures.

Stryker Announces OptaBlunt Bone Tumor Ablation System to Market

{{quote 'The Stryker System for Bone Tumor Ablation (BTA) is a significant improvement on existing technology and complements the Stryker IVS portfolio! There is no more worthy patient contingent for our attention and intervention, and OptaSlate will be life-changing. OptaBlate will help provide another treatment option for those suffering from painful metastatic cancer, and this is just the beginning, said Anthony Brown, a vascular and interventional radiologist at Radiology Imaging Associates. }} OptaBlate also offers a bipedicular approach that allows you to treat two levels of vertebral bodies at once. This allows for faster and more consistent ablation. According to the developers of the system, microinfusion technology provides moisturization of the zone, and active cooperation with medical personnel helped develop a more effective system of ablation of bone tumors to meet their unmet needs. This reduces impedance errors and prevents charring.

Stryker plans to introduce OptaBlate at the North American Spine Society's October 2022 annual meeting in Chicago.^[1]

Notes